On August 31, HENGRUI PHARMA fell 3.05% in regular trading, trading at 46.56 HKD/share, with turnover of approximately 56.25 million HKD. The decline came as the broader pharmaceuticals sector weakened sharply, with CSPC Pharma down 4.46%, Luye Pharma down 11.27%, Hansoh Pharma down 3.43%, and SBP Group down 3.57%.

The selloff follows the company's recently disclosed interim report, which showed first-half revenue of 15.456 billion yuan, down 1.94% year-over-year — marking the first half-year revenue decline in four years. Non-recurring adjusted net profit fell 12.71% to 3.73 billion yuan, signaling weakening core profitability. While innovative drug sales rose 16.38% to 8.809 billion yuan and now account for over 63% of pharmaceutical revenue, legacy generic drug revenue declined 16% due to volume-based procurement pressures on mature products.

Adding to bearish sentiment, JPMorgan raised its short position in HENGRUI PHARMA H-shares from 2.57% to 3.72% as of August 21. BOCOM International maintained a neutral rating and lowered its target price to 57 HKD, citing sustained pressure on existing product lines. Notably, sovereign wealth fund GIC Private Limited made two consecutive purchases totaling approximately 3.7 billion HKD around the same period, lifting its stake to 17.19%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)